What Is SLU-PP-332?
SLU-PP-332 is a synthetic, orally bioavailable small molecule developed at Saint Louis University (from which it takes its "SLU" prefix) as a selective pan-agonist of the estrogen-related receptor (ERR) family. The ERR family consists of three closely related orphan nuclear receptors, ERRα, ERRβ, and ERRγ, which regulate the transcription of genes involved in mitochondrial biogenesis, oxidative phosphorylation, fatty-acid metabolism, and endurance capacity in skeletal muscle.
Unlike the peptide compounds commonly studied in metabolic research, SLU-PP-332 is a small organic molecule rather than a peptide. It has attracted scientific interest as a potential pharmacological "exercise mimetic", a compound capable of producing some of the physiological effects traditionally associated with endurance training, such as improved mitochondrial function and enhanced fatty-acid oxidation, without the mechanical stimulus of exercise itself.
Research Compound Identifier
Full Name: SLU-PP-332
Class: Small-molecule pan-ERR agonist
Target Receptors: ERRα, ERRβ, ERRγ
Route of Administration (research): Typically oral or subcutaneous
Classification: Synthetic small molecule (non-peptide)
Mechanism of Action
SLU-PP-332 exerts its biological effects through activation of the estrogen-related receptor (ERR) family. The ERR receptors regulate a broad transcriptional program related to cellular energy metabolism, and each isoform has overlapping but distinct tissue expression patterns and functional roles.
ERR Activation and Transcriptional Response
Upon binding SLU-PP-332, the ERR receptors translocate to the nucleus and activate target genes that drive mitochondrial biogenesis, oxidative phosphorylation, tricarboxylic acid (TCA) cycle activity, and fatty-acid oxidation. This transcriptional program closely resembles the one activated by endurance exercise, particularly in skeletal muscle.
Skeletal Muscle Oxidative Capacity
In preclinical rodent studies, SLU-PP-332 administration has been reported to increase markers of oxidative muscle fiber content, elevate mitochondrial enzyme activity, and improve running endurance capacity. These findings have been central to the compound's designation as a potential "exercise mimetic" in the research literature.
Fatty Acid Oxidation
Research in obese rodent models has demonstrated that SLU-PP-332 administration can enhance systemic fatty-acid oxidation, reduce adiposity, and improve metabolic markers without a reduction in food intake. These effects are consistent with the known role of ERRα/γ in regulating lipid handling in oxidative tissues.
Insulin Sensitivity
Preclinical metabolic models have reported improvements in insulin sensitivity and glucose handling following chronic SLU-PP-332 administration, effects attributed to enhanced mitochondrial capacity and muscle oxidative metabolism.
Research Overview
SLU-PP-332 was first characterized in the published scientific literature in 2020 and remains a relatively early-stage research compound. The published work to date is predominantly preclinical, focused on metabolic and exercise-physiology questions.
| Research Area | Key Findings | Study Type |
|---|---|---|
| Exercise Capacity | Rodent treadmill studies reported significantly increased endurance running performance with SLU-PP-332 administration | In vivo (rodent) |
| Metabolic / Obesity | Diet-induced obese mice showed reduced adiposity and improved metabolic parameters without decreased caloric intake | In vivo (rodent) |
| Skeletal Muscle Phenotype | Studies observed increased oxidative fiber type markers and mitochondrial density in treated animals | In vivo (rodent) |
| Insulin Sensitivity | Preclinical work has reported improved glucose tolerance and insulin sensitivity in metabolically compromised models | In vivo (rodent) |
| Cardiac Function | Early-stage research has examined ERR activation in cardiac metabolism and heart failure models | In vivo / In vitro |
SLU-PP-332 is an early-stage research compound. It has not entered human clinical trials at the time of publication, and all efficacy and safety data to date come from preclinical animal and cell-based studies. Findings from these models are not directly translatable to human outcomes, and substantially more investigation is required before conclusions can be drawn about human applications.
Common Areas of Research Interest
Scientific investigation of SLU-PP-332 focuses on its exercise-mimetic profile and its implications for metabolic physiology.
- Exercise mimetic research, Studies examine whether SLU-PP-332 can reproduce key physiological adaptations to endurance exercise without the mechanical stimulus
- Obesity and metabolic disease, Preclinical work investigates effects on fat mass, lipid metabolism, and insulin sensitivity in obese and metabolically dysfunctional models
- Sarcopenia and muscle disuse, Research examines whether ERR activation can counteract muscle atrophy or fiber-type shifts associated with inactivity or aging
- Mitochondrial dysfunction, Given ERRs' role in mitochondrial biogenesis, investigation has explored SLU-PP-332 in conditions characterized by mitochondrial insufficiency
- Cardiac metabolism, Early-stage studies have looked at ERR activation in cardiac tissue, where oxidative metabolism is critical
Pharmacokinetics
SLU-PP-332 is an orally bioavailable small molecule, a profile that distinguishes it from most peptide compounds. Its pharmacokinetic characterization remains limited to early published work and ongoing preclinical investigation.
Unlike peptides, which are typically administered parenterally due to enzymatic degradation in the digestive tract, SLU-PP-332's small-molecule structure confers oral bioavailability in preclinical models. This has been highlighted as an advantage for translational research, as it simplifies dosing protocols relative to injectable peptide-based compounds.
Comparison to Similar Compounds
SLU-PP-332 is often compared to other compounds investigated for metabolic or exercise-mimetic effects, even when their underlying mechanisms differ.
| Feature | SLU-PP-332 | GW501516 (Cardarine) | MOTS-c |
|---|---|---|---|
| Class | Small molecule | Small molecule | Mitochondrial-derived peptide |
| Primary Target | ERRα, ERRβ, ERRγ | PPARδ | AMPK, folate cycle |
| Research Focus | Exercise capacity, mitochondrial biogenesis | Fatty-acid oxidation, endurance | Insulin sensitivity, metabolism |
| Route (research) | Oral / subcutaneous | Oral | Subcutaneous |
Frequently Asked Questions
Sources & References
- Billon C, et al. "Synthetic ERRα/β/γ Agonist Induces an ERRα-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity." ACS Chemical Biology. 2023;18(4):756-771. PubMed
- Billon C, et al. "A synthetic ERR agonist alleviates metabolic syndrome." The Journal of Pharmacology and Experimental Therapeutics. 2024;388(2):232-240. PubMed
- Giguère V. "Transcriptional control of energy homeostasis by the estrogen-related receptors." Endocrine Reviews. 2008;29(6):677-696. PubMed
- Huss JM, et al. "The nuclear receptor ERRalpha is required for the bioenergetic and functional adaptation to cardiac pressure overload." Cell Metabolism. 2007;6(1):25-37. PubMed
- Narkar VA, et al. "Exercise and PGC-1α-independent synchronization of type I muscle metabolism and vasculature by ERRγ." Cell Metabolism. 2011;13(3):283-293. PubMed
Explore SLU-PP-332
Available for research purposes. Third-party tested for purity and identity.
View SLU-PP-332 Products — $140This product is intended for research and laboratory use only. It is not intended for human consumption.